JPWO2009147831A1 - 精神障害の治療方法および治療用医薬組成物 - Google Patents
精神障害の治療方法および治療用医薬組成物 Download PDFInfo
- Publication number
- JPWO2009147831A1 JPWO2009147831A1 JP2010515767A JP2010515767A JPWO2009147831A1 JP WO2009147831 A1 JPWO2009147831 A1 JP WO2009147831A1 JP 2010515767 A JP2010515767 A JP 2010515767A JP 2010515767 A JP2010515767 A JP 2010515767A JP WO2009147831 A1 JPWO2009147831 A1 JP WO2009147831A1
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical composition
- depression
- mental
- fibromyalgia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 39
- 208000020016 psychiatric disease Diseases 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 22
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 208000002193 Pain Diseases 0.000 claims abstract description 33
- 230000036407 pain Effects 0.000 claims abstract description 31
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 22
- 206010012289 Dementia Diseases 0.000 claims abstract description 19
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 19
- 206010022437 insomnia Diseases 0.000 claims abstract description 19
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 13
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims abstract description 13
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims abstract description 13
- 208000032841 Bulimia Diseases 0.000 claims abstract description 11
- 208000035475 disorder Diseases 0.000 claims abstract description 11
- 206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 10
- 208000019906 panic disease Diseases 0.000 claims abstract description 9
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 9
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 8
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 7
- 208000020925 Bipolar disease Diseases 0.000 claims abstract description 7
- 201000007930 alcohol dependence Diseases 0.000 claims abstract description 6
- 230000002829 reductive effect Effects 0.000 claims abstract description 6
- 206010041250 Social phobia Diseases 0.000 claims abstract description 5
- 208000028683 bipolar I disease Diseases 0.000 claims abstract description 5
- 208000018459 dissociative disease Diseases 0.000 claims abstract description 5
- 201000002859 sleep apnea Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 48
- 229940079593 drug Drugs 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 27
- 208000024891 symptom Diseases 0.000 claims description 22
- 239000002249 anxiolytic agent Substances 0.000 claims description 16
- 239000000164 antipsychotic agent Substances 0.000 claims description 14
- 230000000949 anxiolytic effect Effects 0.000 claims description 14
- 229940053544 other antidepressants in atc Drugs 0.000 claims description 13
- 239000001961 anticonvulsive agent Substances 0.000 claims description 12
- AVZIYZHXZAYGJS-UHFFFAOYSA-N Difenidol hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 AVZIYZHXZAYGJS-UHFFFAOYSA-N 0.000 claims description 10
- 206010012239 Delusion Diseases 0.000 claims description 8
- 230000003556 anti-epileptic effect Effects 0.000 claims description 8
- 231100000868 delusion Toxicity 0.000 claims description 8
- 229940054010 other antipsychotics in atc Drugs 0.000 claims description 7
- 229940053982 other anxiolytics in atc Drugs 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 229960003135 donepezil hydrochloride Drugs 0.000 claims description 6
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003326 hypnotic agent Substances 0.000 claims description 6
- 230000000147 hypnotic effect Effects 0.000 claims description 6
- 229940053180 other antiepileptics in atc Drugs 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 6
- 229940005529 antipsychotics Drugs 0.000 claims description 5
- 229940005530 anxiolytics Drugs 0.000 claims description 5
- 206010012218 Delirium Diseases 0.000 claims description 4
- 229960005058 diphenidol hydrochloride Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 238000013329 compounding Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000022821 personality disease Diseases 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 description 13
- 239000000935 antidepressant agent Substances 0.000 description 11
- 229940005513 antidepressants Drugs 0.000 description 11
- 238000013268 sustained release Methods 0.000 description 11
- 239000012730 sustained-release form Substances 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 10
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 10
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 10
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 230000036506 anxiety Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 206010016256 fatigue Diseases 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 229960003520 diphenidol Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 208000019022 Mood disease Diseases 0.000 description 6
- 230000001430 anti-depressive effect Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
- 208000020401 Depressive disease Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229960003530 donepezil Drugs 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 102000010909 Monoamine Oxidase Human genes 0.000 description 4
- 108010062431 Monoamine oxidase Proteins 0.000 description 4
- 208000012886 Vertigo Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- -1 metalbital Chemical compound 0.000 description 4
- 231100000889 vertigo Toxicity 0.000 description 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- 229940125713 antianxiety drug Drugs 0.000 description 3
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 3
- 229960003012 cefamandole Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000003001 depressive effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 208000013465 muscle pain Diseases 0.000 description 3
- 229960002296 paroxetine Drugs 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 208000027601 Inner ear disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229940005524 anti-dementia drug Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229960004404 etizolam Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000008717 functional decline Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960000600 milnacipran Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- AXWLKJWVMMAXBD-UHFFFAOYSA-N 1-butylpiperidine Chemical class CCCCN1CCCCC1 AXWLKJWVMMAXBD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000027559 Appetite disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000025967 Dissociative Identity disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 229940125682 antidementia agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003533 ethotoin Drugs 0.000 description 1
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229940061816 fluoxetine 60 mg Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229940124711 schizophrenia therapeutics Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 210000003273 vestibular nerve Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
注意欠陥・多動性障害(ADHD)、及び暴力行為を頻繁に起こす女性37歳。路上でマナーの悪い人を見ると、注意して口論になり、叩く等の暴力が、1週間に1−2回起こっていた。抗てんかん薬、抗不安薬で効果がなく、セファドール75mg/1日を投与したところ、2日目で衝動性が改善され、7日目で衝動性が消失した。セファドール75mgの投与を中止したところ、元の状態に戻った。効果発現に2日、中止後、症状は5日間で元に戻った。副作用はなかった。
抗うつ薬が無効例の女性42歳
SSRI、SNRI、三環系、抗不安薬の組み合わせを、各々最大量試したが、効果なく、HAMDは23点であった。セファドール75mg/1日投与に変更したところ、自覚的にうつが改善された。セファドール投与量を150mg/1日にしたところ、HAMDは3点に改善された。他の抗うつ薬を取り去っても効果が続いている。3ヶ月後でも、HAMDは3点であった。セファドール投与量を75mg/1日にしたところ(一週間後)、HAMDは13点になった。副作用はなかった。
男性42歳
躁うつ病の躁期(双極性I型の躁期)が1ヶ月以上続き、抗てんかん薬で無効、リーマス1,200mgで無効、抗精神病薬は副作用が大きく、使えなかった。セファドール150mg/1日投与に切り替えたところ寛解、セファドールの投与を中止すると5日目に躁が出現した。副作用はなかった。
アルツハイマー性認知症の男性76歳
塩酸ドネペジルを使用すると、興奮が起こり、使用できなかった男性について、セファドール50mgを寝る前に追加投与することにより、興奮がなくなり、塩酸ドネペジルが投与可能となり、認知症も改善した。副作用はなかった。
認知症の周辺症状に対する効果
女性82歳
認知症及び怒りっぽい、興奮しやすい、被害妄想がある人に、セファドール100mg/1日の投与によって、精神的に安定し、被害妄想による、他者への迷惑行為がなくなった。副作用はなかった。
アルコール依存症
男性45歳 会社員
1日1〜2リットルのビール、及び焼酎、水割り3〜5杯が止まらず、日曜日は午前中からアルコールを飲用していて、肝機能障害を合併していた。シアナマイド、抑うつ薬を使用したが、全て無効であった。セファドール150mg/1日を投与したところ、翌日に、渇酒の衝動が消失して、同時に、焦燥感、不安感も消失した。3ヶ月服用を続けて、アルコール乱用が出現していない。副作用はなかった。
過食症(1)
26歳女性
18歳から過食症が出現した。抗うつ薬、抗不安薬、その他が全く無効であった。セファドール150mg/1日で、1日2〜3回あった過食が消失した。効果出現まで2日を要した。副作用はなかった。
過食症(2)
31歳女性 主婦
18歳より過食症が出現、結婚して1児をもうけるも、過食症は続いていた。個人輸入でプロザック(prozac)40mgを服用して、過食症がやや軽快していた。1日に2〜3回の過食と嘔吐が、1日1回に減ったが、ゼロにはならなかった。セファドール150mg/1日投与にしたところ、過食が止まった。2ヶ月以上効果が持続している。副作用はなかった。
うつ病の症例
32歳男性 会社員
パキシル(paroxetine)40mgでなお、うつが改善しない男性に対し、セファドール75mg/1日を投与したところ、HAMD20点が3日後に7点にまで減少した。副作用はなかった。
パニック障害及び、多重人格に対して
35歳女性 独身
18歳から、精神科に通院中である。これまで7人の精神科医にかかり、存在する殆どすべての精神科の薬を服用しても、効果がない重症例である。セファドール75mg/1日を1週間投与した後、セファドール150mg/1日の投与で、パニック障害が改善し、それまで、1ヶ月に5〜10回起こっていた人格変換がなおった。本人曰く、「これまでのどの薬より、気持ちが安定して飲みやすい」。副作用はなかった。セファドールに強い抗不安効果があることがわかった。
老人の不眠症
78歳男性
定年までは会社員として不眠・うつ病の既往はなかった。70歳を過ぎた頃から、不眠が出現し、本人はそのことでとても悩み、2〜3ヵ所の精神科で眠剤の処方を受けていた。ところが、夜中トイレに行く時にころび易く、又朝がボーっとしていて記憶障害も出現していた。この患者にセファドール50mg×2回(夕食後、眠前)に投与したところ快眠となり、睡眠薬も2分の1に減量し、夜中起きている時のフラツキはなくなり、翌朝の気分もよく、記憶障害もなくなった。副作用はなかった。
統合失調症の症例
45歳男性
20歳より統合失調症の診断で抗精神病薬を服用している。最新の抗精神病薬を服用しても頭の回転の鈍さ、抑うつ、肥満が改善されないところ、セファドール150mg/1日投与にしたところ服用後、食欲が低下し、体重が減少傾向となり、自覚的、他覚的な思考の速度、抑うつが改善してQOLが上がった。しかも副作用はなく、また統合失調症の再燃はなかった。
男性35歳 会社員
パキシル10mg、ロヒプノール2mg、デパス2mgを就寝前に飲んで減らそうとすると、退薬症状が出て減らせないところ、まず、セファドールを夕食後25mg、寝る前50mg、飲むことによって、いずれの薬も2週間までに離脱できた。更に、セファドール投与量を50mg−25mg−0mgと減量した事によって、薬の中断が可能となった。副作用はなかった。
肩凝りは自覚症状としては、頻繁に見られ、日常生活上、普通に見られる重大な愁訴の一つである。肩凝りを訴えた7名について、セファドール(25mg)2錠を、2回(夕食後、寝る前)投与したところ、全員について、2日目には、症状の消失ないし、大幅な軽減が見られた。
56歳 女性(主婦)
3年前、他の線維筋痛症の専門医にかかり、線維筋痛症の診断を受けた。その後3年間、非ステロイド性消炎鎮痛剤、抗不安薬や三環系抗うつ薬トリプタノール、SSRI、SNRI等の薬を最大量試みるが、全く改善しなかったため、当院を受診した。
34歳 女性(主婦)
6年間、当クリニックで治療中であった。全身の倦怠感、疲労感、抑うつ、不眠、肩こり及び全身の痛みが続いていた。抑うつについては、ハミルトンのD スケールで25〜28であった。血液学的な異常は認められなかった。圧痛点の検査を含め、総合的に判断し、線維筋痛症と診断した。
58歳 女性(主婦)
他院で線維筋痛症と診断された。処方された薬では効果がなく、ストレッチや軽いマッサージ、患部を温めることなどを指導された。しかし、関節痛がひどく、ストレッチやその他の指導を実践する事ができなかった。全身の圧痛点の18箇所全てに痛みがあり、顎のこわばり、及び、両ひざ関節の痛みが強く、徒歩で通院できなかった。
42歳 女性 (主婦)
7年前から、うつ病で通院中の患者である。微熱が続いたり、慢性の頭痛、倦怠感が強く、血液検査を行ったが、自己免疫疾患、及び、炎症性疾患は否定された。背部痛と指先の痛みにより家事はできず、軽いものでも手に取る事が苦痛であった。18箇所の圧痛点のうち15箇所で圧痛がみられたことから、線維筋痛症と診断した。抗うつ薬の全てに反応せず、SNRI(ミルナシプラン)では逆に背部痛が悪化した。一日中横になっている状態が長期間にわたり続いた。セファドールを75mg/dayを投与から開始しところ、倦怠感が改善。その後、125mg/dayにしたところ、背部痛と指先痛み等が改善し、家事がおこなえるまで回復した。全身の関節が柔らかくなったと主観的に感じた。他覚的にも大きな関節の可動性が増大した。
Claims (17)
- 1,1−ジフェニル−4−ピペリジン−1−イルブタン−1−オール又はその医薬的に許容される塩を含むことを特徴とする、精神障害の治療用医薬組成物。
- 前記精神障害が、うつ病、躁うつ病、不安障害、衝動性障害、過食症、パニック障害、社会不安障害、不眠症、注意欠陥多動性障害(ADHD)、統合失調症、認知症、人格障害、アルコール依存症、解離性障害、睡眠時無呼吸症候群、又は線維筋痛症である請求項1に記載の医薬組成物。
- 塩酸ジフェニドールを含む請求項1に記載の医薬組成物。
- 他の抗うつ薬、抗不安薬、抗精神病薬、抗てんかん薬又は睡眠薬と組み合わせてなる請求項1に記載の医薬組成物。
- 前記他の抗うつ薬、抗不安薬、抗精神病薬、抗てんかん薬若しくは睡眠薬と組み合わせて投与されるか、又は当該薬剤による治療を中止した後に単独で投与されることを特徴とする請求項4に記載の医薬組成物。
- 前記精神障害が、線維筋痛症、慢性疲労症候群(CFS)又は痛みを伴ったうつ病であり、これらの精神障害によって引き起こされる痛みを軽減する請求項1に記載の医薬組成物。
- 1,1−ジフェニル−4−ピペリジン−1−イルブタン−1−オール又はその医薬的に許容される塩を含むことを特徴とする、認知症に伴う不眠症、せん妄、又はその周辺症状(被害妄想、徘徊、暴力行為)を改善するための医薬組成物。
- 塩酸ドネペジルとの配合剤である請求項7に記載の医薬組成物。
- 肩凝り改善作用を有する請求項1に記載の医薬組成物。
- 1,1−ジフェニル−4−ピペリジン−1−イルブタン−1−オール又はその医薬的に許容される塩を含む医薬組成物の有効量を、精神障害の治療の必要がある患者に投与することを特徴とする精神障害の治療方法。
- 前記精神障害が、うつ病、躁うつ病、不安障害、衝動性障害、過食症、パニック障害、社会不安障害、不眠症、注意欠陥多動性障害(ADHD)、統合失調症、認知症、人格障害、アルコール依存症、解離性障害、睡眠時無呼吸症候群、又は線維筋痛症である請求項10に記載の方法。
- 塩酸ジフェニドールを含む請求項10に記載の方法。
- 前記医薬組成物が、他の抗うつ薬、抗不安薬、抗精神病薬、抗てんかん薬又は睡眠薬と組み合わせて患者に投与される請求項10に記載の方法。
- 前記医薬組成物が他の抗うつ薬、抗不安薬、抗精神病薬、抗てんかん薬若しくは睡眠薬と組み合わせて投与されるか、又は他の抗うつ薬、抗不安薬、抗精神病薬、抗てんかん薬若しくは睡眠薬による治療を中止した後に単独で投与されることを特徴とする請求項13に記載の方法。
- 前記精神障害が、線維筋痛症、慢性疲労症候群(CFS)又は痛みを伴ったうつ病であり、これらの精神障害によって引き起こされる痛みを軽減する請求項10に記載の方法。
- 1,1−ジフェニル−4−ピペリジン−1−イルブタン−1−オール又はその医薬的に許容される塩を含む医薬組成物の有効量を、認知症に伴う不眠症、せん妄、又はその周辺症状(被害妄想、徘徊、暴力行為)を治療する必要がある患者に投与することを特徴とする精神障害の治療方法。
- 前記医薬組成物が、塩酸ドネペジルとの配合剤である請求項16に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010515767A JP5436419B2 (ja) | 2008-06-04 | 2009-06-02 | 精神障害の治療方法および治療用医薬組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008146755 | 2008-06-04 | ||
JP2008146755 | 2008-06-04 | ||
PCT/JP2009/002455 WO2009147831A1 (ja) | 2008-06-04 | 2009-06-02 | 精神障害の治療方法および治療用医薬組成物 |
JP2010515767A JP5436419B2 (ja) | 2008-06-04 | 2009-06-02 | 精神障害の治療方法および治療用医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2009147831A1 true JPWO2009147831A1 (ja) | 2011-10-20 |
JP5436419B2 JP5436419B2 (ja) | 2014-03-05 |
Family
ID=41397914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010515767A Active JP5436419B2 (ja) | 2008-06-04 | 2009-06-02 | 精神障害の治療方法および治療用医薬組成物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20110065749A1 (ja) |
JP (1) | JP5436419B2 (ja) |
WO (1) | WO2009147831A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6667226B2 (ja) * | 2015-08-19 | 2020-03-18 | 花王株式会社 | 不定愁訴症状の状態の分類のための指標を取得する方法 |
CN110551079B (zh) * | 2019-09-10 | 2021-04-06 | 株洲千金药业股份有限公司 | 一种高纯度盐酸地芬尼多的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2725445B1 (fr) * | 1994-10-10 | 1996-10-31 | Adir | Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JPH08239327A (ja) * | 1995-03-03 | 1996-09-17 | Taisho Pharmaceut Co Ltd | 慢性骨格筋疼痛の予防又は治療剤 |
EP0819001A1 (de) * | 1995-04-05 | 1998-01-21 | Byk Gulden Lomberg Chemische Fabrik GmbH | Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten |
WO2006013833A1 (ja) * | 2004-08-02 | 2006-02-09 | Kyoto University | 新規な抗不安剤 |
-
2009
- 2009-06-02 WO PCT/JP2009/002455 patent/WO2009147831A1/ja active Application Filing
- 2009-06-02 JP JP2010515767A patent/JP5436419B2/ja active Active
- 2009-06-02 US US12/992,681 patent/US20110065749A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2009147831A1 (ja) | 2009-12-10 |
JP5436419B2 (ja) | 2014-03-05 |
US20110065749A1 (en) | 2011-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019203832B2 (en) | Fenfluramine for use in the treatment of dravet syndrome | |
US20060122127A1 (en) | Methods for reducing the side effects associated with mirtzapine treatment | |
Wichniak et al. | Sleep and antidepressant treatment | |
EP3272343B1 (en) | Tapentadol for preventing and treating depression and anxiety | |
US6395788B1 (en) | Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine | |
US6335021B1 (en) | Composition for controlling mood disorders in healthy individuals | |
CZ20014226A3 (cs) | Nové pouľití 1-[4-(5-kyanoindol-3-yl)butyl]-4-(2-karbamoyl-benzofuran-5-yl)piperazinu a jeho fyziologicky přijatelných solí | |
JP2009500420A (ja) | エスゾピクロン及びo−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法 | |
JP2009500421A (ja) | エスゾピクロン及び抗うつ薬の組み合わせ | |
US20100160294A1 (en) | Tolerability of mirtazapine and a second active by using them in combination | |
US20160256449A1 (en) | H3 receptor antagonist for use in the treatment of alzheimer's disease | |
US20090275562A1 (en) | Tolerability of mirtazapine and a second active by using them in combination | |
Ban | The treatment of depressed geriatric patients | |
Winkelman et al. | Current patterns and future directions in the treatment of insomnia | |
JP5436419B2 (ja) | 精神障害の治療方法および治療用医薬組成物 | |
KR20230004670A (ko) | 다리도렉산트의 의학적 용도 | |
CN114555070A (zh) | 月经周期诱发的症状治疗 | |
TW200528098A (en) | Treatment of insomnia in human patients | |
JP7034314B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
CA2139896C (en) | Use of antinauseant agent for terminally ill humans | |
Rani et al. | Aetiopahogenesis and management of chronic urticaria-A Study | |
Kuśnierz et al. | Depression and its treatment with trazodone | |
Templer et al. | Psychotropic drugs in terminally ill patients: A review of the clinical and research literature | |
JPH03246225A (ja) | メランコリーうつ病の治療法 | |
US20130267533A1 (en) | 5ht1a agonists for treatment of high cholesterol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120411 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120411 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130920 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131203 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5436419 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |